Unlocking healthcare potential for patients
Leveraging our expertise to address unmet medical needs
Our Strategy
Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas.
Mereo BioPharma plans to build a rare and orphan disease commercial business based on products acquired from major pharmaceutical companies.
our products
Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharma AG.
Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies.
Pre-Clinical
Phase 1
Phase 2
Phase 3
BPS-804
Osteogenesis Imperfecta (OI)BGS-649
Hypogonadotropic Hypogonadism (HH) in Obese MenACUMAPIMOD
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)Investors
Share Price
Events and conferences
- 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017
- 24 Jan 2017 Mereo BioPharma presented at at the Shares Spotlight Evening in London
- 10 Jan 2017 Mereo BioPharma Group plc presented at the 9th Annual Biotech Showcase, 11:00am PST (San Francisco, USA)